Chen Dapeng, Li Ying, Mei Yan, Geng Wenjia, Yang Jurong, Hong Quan, Feng Zhe, Cai Guangyan, Zhu Hanyu, Shi Suozhu, Bai Xue-Yuan, Chen Xiangmei
State Key Laboratory of Kidney Diseases (2011DAV00088), Department of Nephrology, Chinese PLA Institute of Nephrology, National Clinical Research Center for Kidney Disease (2013BAI09B05), Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China.
Cell Mol Life Sci. 2014 Oct;71(20):4027-42. doi: 10.1007/s00018-014-1599-y. Epub 2014 Mar 18.
The main pathological characteristic of glomerulonephritis is diffuse mesangial cell proliferation. MiR-34a is associated with the proliferation of various organs and cancer cells. However, the role of miR-34a in renal proliferation diseases is not clear. Therefore, this study aimed to elucidate the mechanism of miR-34a in the regulation of renal mesangial cell proliferation. The miR-34a expression level at different time points in an anti-Thy1 mesangial proliferative nephritis rat model was determined by qRT-PCR. The cell proliferation rate and cell cycle changes were measured in the in vitro cultured rat mesangial cells (RMCs). Our results suggested that miR-34a expression was negatively correlated with the degree of cell proliferation in the anti-Thy1 nephritis model. MiR-34a could extend the G0/G1 phase and block cell proliferation in RMCs. Dual-luciferase assay results showed that there were binding sites of miR-34a at 3'-UTR of platelet-derived growth factor receptor-β (PDGFR-β). MiR-34a can inhibit PDGFR-β protein expression at a post-transcriptional level, suppress Ras/MAPK signaling pathways, and down-regulate expression of cell cycle proteins at the G0/G1 phase, such as cyclin D1, CDK4/CDK6. In addition, miR-34a may also inhibit RMC proliferation by directly targeting cyclin E and CDK2. MiR-34a inhibits exogenous stimuli-induced proliferation of mesangial cells. Expression levels of phospho-PDGFR-β and phospho-MEK1 (an important downstream molecule in PDGFR-β-induced signaling pathway) were significantly increased in the anti-Thy-1 nephritis rat model. These results suggest that miR-34a may regulate RMC proliferation by directly inhibiting expressions of PDGFR-β, MEK1, and cell cycle proteins, cyclin E and CDK2.
肾小球肾炎的主要病理特征是弥漫性系膜细胞增生。miR-34a与各种器官和癌细胞的增殖相关。然而,miR-34a在肾脏增殖性疾病中的作用尚不清楚。因此,本研究旨在阐明miR-34a调控肾系膜细胞增殖的机制。通过qRT-PCR测定抗Thy1系膜增生性肾炎大鼠模型中不同时间点的miR-34a表达水平。在体外培养的大鼠系膜细胞(RMCs)中测量细胞增殖率和细胞周期变化。我们的结果表明,在抗Thy1肾炎模型中,miR-34a表达与细胞增殖程度呈负相关。miR-34a可以延长RMCs的G0/G1期并阻断细胞增殖。双荧光素酶测定结果显示,血小板衍生生长因子受体-β(PDGFR-β)的3'-UTR存在miR-34a的结合位点。miR-34a可以在转录后水平抑制PDGFR-β蛋白表达,抑制Ras/MAPK信号通路,并下调G0/G1期细胞周期蛋白的表达,如细胞周期蛋白D1、CDK4/CDK6。此外,miR-34a还可能通过直接靶向细胞周期蛋白E和CDK2抑制RMC增殖。miR-34a抑制外源性刺激诱导的系膜细胞增殖。在抗Thy-1肾炎大鼠模型中,磷酸化PDGFR-β和磷酸化MEK1(PDGFR-β诱导信号通路中的重要下游分子)的表达水平显著升高。这些结果表明,miR-34a可能通过直接抑制PDGFR-β、MEK1以及细胞周期蛋白E和CDK2的表达来调节RMC增殖。